JP2011522795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522795A5 JP2011522795A5 JP2011508582A JP2011508582A JP2011522795A5 JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5 JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011508582 A JP2011508582 A JP 2011508582A JP 2011522795 A5 JP2011522795 A5 JP 2011522795A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- molecule
- composition according
- region
- ctla4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5033608P | 2008-05-05 | 2008-05-05 | |
| US61/050,336 | 2008-05-05 | ||
| US12/387,359 | 2009-05-01 | ||
| US12/387,359 US7915222B2 (en) | 2008-05-05 | 2009-05-01 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| PCT/US2009/042761 WO2009137424A1 (en) | 2008-05-05 | 2009-05-05 | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522795A JP2011522795A (ja) | 2011-08-04 |
| JP2011522795A5 true JP2011522795A5 (enExample) | 2012-03-15 |
Family
ID=41264941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508582A Pending JP2011522795A (ja) | 2008-05-05 | 2009-05-05 | 未分類関節炎を有する対象における関節リウマチの発症を予防するための方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7915222B2 (enExample) |
| EP (2) | EP2279206B1 (enExample) |
| JP (1) | JP2011522795A (enExample) |
| KR (1) | KR20110014180A (enExample) |
| CN (1) | CN102037010A (enExample) |
| AR (1) | AR071672A1 (enExample) |
| AU (1) | AU2009244448B2 (enExample) |
| BR (1) | BRPI0912249A2 (enExample) |
| CA (1) | CA2723698C (enExample) |
| CL (1) | CL2009001082A1 (enExample) |
| DK (1) | DK2279206T3 (enExample) |
| EA (1) | EA201001749A1 (enExample) |
| ES (1) | ES2539840T3 (enExample) |
| HK (1) | HK1208230A1 (enExample) |
| HR (1) | HRP20150552T1 (enExample) |
| HU (1) | HUE025256T2 (enExample) |
| IL (1) | IL208691A (enExample) |
| MX (1) | MX2010011503A (enExample) |
| NZ (1) | NZ589020A (enExample) |
| PL (1) | PL2279206T3 (enExample) |
| PT (1) | PT2279206E (enExample) |
| SI (1) | SI2279206T1 (enExample) |
| TW (2) | TWI454278B (enExample) |
| WO (1) | WO2009137424A1 (enExample) |
| ZA (1) | ZA201007914B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| JP6239517B2 (ja) * | 2011-10-10 | 2017-11-29 | メディミューン リミテッド | 関節リウマチの治療法 |
| US20140006055A1 (en) * | 2012-06-27 | 2014-01-02 | Iagnosis, Inc. | Integrated Medical Evaluation and Record Keeping System |
| WO2014070840A2 (en) * | 2012-10-30 | 2014-05-08 | Emory University | Stimulating bone formation by inhibition of cd28 co-stimulation |
| WO2014151230A2 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
| SG11201608848XA (en) * | 2014-04-25 | 2016-11-29 | Bristol Myers Squibb Co | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2019074983A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN110148465B (zh) * | 2019-05-10 | 2023-07-04 | 中山大学孙逸仙纪念医院 | 一种用于分析类风湿性关节炎的系统 |
| WO2021226551A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| EP0683793A4 (en) * | 1993-01-21 | 1997-04-09 | Univ Georgia Res Found | VACCINE AND METHODS FOR PREVENTION AND TREATMENT OF Fescue Toxicity In Herbivorous Animals. |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| AU710998B2 (en) | 1996-03-20 | 1999-10-07 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith |
| US20030219863A1 (en) | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| EP1294391B1 (en) | 2000-06-09 | 2012-08-15 | Bristol-Myers Squibb Company | Combination of agents for inhibiting transplant rejection |
| SI1935427T1 (en) * | 2000-07-03 | 2018-05-31 | Bristol-Myers Squibb Company | USE OF HEATED CTLA4 MUTANT MOLECULES |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| HUP0303930A3 (en) | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
| US7332303B2 (en) | 2002-12-23 | 2008-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
| AU2003300276B2 (en) | 2002-12-23 | 2010-07-01 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| EP1895898B1 (en) | 2005-06-29 | 2011-02-16 | Compumedics Limited | Sensor assembly with conductive bridge |
| US8702777B2 (en) * | 2005-08-22 | 2014-04-22 | Incept, Llc | Steep-taper flared stents and apparatus and methods for delivering them |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| US7528111B2 (en) | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
-
2009
- 2009-05-01 US US12/387,359 patent/US7915222B2/en active Active
- 2009-05-05 CA CA2723698A patent/CA2723698C/en active Active
- 2009-05-05 KR KR1020107027221A patent/KR20110014180A/ko not_active Ceased
- 2009-05-05 CL CL2009001082A patent/CL2009001082A1/es unknown
- 2009-05-05 ES ES09743410.4T patent/ES2539840T3/es active Active
- 2009-05-05 EP EP20090743410 patent/EP2279206B1/en active Active
- 2009-05-05 NZ NZ589020A patent/NZ589020A/en not_active IP Right Cessation
- 2009-05-05 PL PL09743410T patent/PL2279206T3/pl unknown
- 2009-05-05 HR HRP20150552TT patent/HRP20150552T1/hr unknown
- 2009-05-05 SI SI200931228T patent/SI2279206T1/sl unknown
- 2009-05-05 AU AU2009244448A patent/AU2009244448B2/en not_active Ceased
- 2009-05-05 TW TW098114831A patent/TWI454278B/zh not_active IP Right Cessation
- 2009-05-05 CN CN2009801162049A patent/CN102037010A/zh active Pending
- 2009-05-05 EP EP15152246.3A patent/EP2891665A1/en not_active Withdrawn
- 2009-05-05 PT PT97434104T patent/PT2279206E/pt unknown
- 2009-05-05 MX MX2010011503A patent/MX2010011503A/es active IP Right Grant
- 2009-05-05 TW TW103129409A patent/TW201444575A/zh unknown
- 2009-05-05 DK DK09743410.4T patent/DK2279206T3/en active
- 2009-05-05 BR BRPI0912249A patent/BRPI0912249A2/pt not_active Application Discontinuation
- 2009-05-05 WO PCT/US2009/042761 patent/WO2009137424A1/en not_active Ceased
- 2009-05-05 HU HUE09743410A patent/HUE025256T2/en unknown
- 2009-05-05 EA EA201001749A patent/EA201001749A1/ru unknown
- 2009-05-05 JP JP2011508582A patent/JP2011522795A/ja active Pending
- 2009-05-05 AR ARP090101621A patent/AR071672A1/es unknown
-
2010
- 2010-10-13 IL IL208691A patent/IL208691A/en not_active IP Right Cessation
- 2010-11-04 ZA ZA2010/07914A patent/ZA201007914B/en unknown
-
2011
- 2011-02-10 US US13/024,601 patent/US8435952B2/en active Active
- 2011-03-07 HK HK15108768.6A patent/HK1208230A1/en unknown
-
2013
- 2013-03-27 US US13/851,166 patent/US9012408B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2505603C2 (ru) | Антитело против рецептора il-6 | |
| HRP20150552T1 (hr) | Metoda za sprjeäśavanje razvoja reumatoidnog artritisa kod podložnih osoba s nediferenciranim artritisom | |
| JP2010511388A5 (enExample) | ||
| JP2010529957A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2021511826A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| HRP20231066T1 (hr) | Bcma (cd269/tnfrsf17) - vezujući proteini | |
| JP2015508757A5 (enExample) | ||
| JP2017528419A5 (enExample) | ||
| JP2010500005A5 (enExample) | ||
| NZ603623A (en) | Tcr complex immunotherapeutics | |
| JP2004248677A5 (enExample) | ||
| JP2012500020A5 (enExample) | ||
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| JP2019507589A5 (enExample) | ||
| PE20131334A1 (es) | Anticuerpo igg1 humanizado | |
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| JP2010533498A5 (enExample) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2011524420A5 (enExample) | ||
| JP2016512213A5 (enExample) |